|Articles|May 1, 2002
- Applied Clinical Trials-05-01-2002
Identifying and Documenting Adverse Events at Clinical Study Sites
Improving adverse event reporting can lead to improved safety profiles and, consequently, fewer drugs pulled from the market.
Advertisement
Articles in this issue
about 24 years ago
Letters to the Editorabout 24 years ago
Parents for Orphansabout 24 years ago
Fraud, Abuse, and Consentabout 24 years ago
Brian Koziolabout 24 years ago
A Model-Based Method for Improving Protocol QualityAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy
2
Bringing the Voice of Clinical Practice and Patients into Drug Development
3
ACT Brief: Single Pivotal Trial Stakes, Configurable FSP Strategy, and G-CSF Biosimilar Portfolio Expansion
4
Tailoring Your FSP Approach: Why One Model Doesn’t Fit Every Trial
5